Clinical data | |
---|---|
Trade names | Solu-Medrol, Solu-Medrone, Urbason, others |
Other names | Methylprednisolone hemisuccinate; 6α-Methylprednisolone 21-hemisuccinate |
AHFS/Drugs.com | Monograph |
License data | |
Routes of administration | Intravenous injection |
Drug class | Corticosteroid; Glucocorticoid |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.017.416 |
Chemical and physical data | |
Formula | C26H34O8 |
Molar mass | 474.550 g·mol−1 |
3D model (JSmol) | |
| |
|
Methylprednisolone succinate, sold under the brand name Solu-Medrol among others, is a synthetic glucocorticoid corticosteroid and a corticosteroid ester—specifically the C21 succinate ester of methylprednisolone—which is used by intravenous administration.[3][4] Methylprednisolone succinate is provided as two different salts when used as a pharmaceutical drug: a sodium salt (methylprednisolone sodium succinate; brand name Solu-Medrol, others) and a hydrogen salt (methylprednisolone hemisuccinate or methylprednisolone hydrogen succinate; brand name Urbason).[3][4]
Methylprednisolone succinate was approved for medical use in the United States in 1959.[2]